Interventional Cardio-Oncology: Adding a New Dimension to the Cardio-Oncology Field
The management of cardiovascular disease in patients with active cancer presents a unique challenge in interventional cardiology. Cancer patients often suffer from significant comorbidities such as thrombocytopenia and coagulopathic and/or hypercoagulable states, which complicates invasive evaluatio...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2018-05-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fcvm.2018.00048/full |
| _version_ | 1818113615066038272 |
|---|---|
| author | Victor Y. Liu Ali M. Agha Juan Lopez-Mattei Juan Lopez-Mattei Nicolas Palaskas Peter Kim Kara Thompson Elie Mouhayar Konstantinos Marmagkiolis Saamir A. Hassan Kaveh Karimzad Cezar A. Iliescu |
| author_facet | Victor Y. Liu Ali M. Agha Juan Lopez-Mattei Juan Lopez-Mattei Nicolas Palaskas Peter Kim Kara Thompson Elie Mouhayar Konstantinos Marmagkiolis Saamir A. Hassan Kaveh Karimzad Cezar A. Iliescu |
| author_sort | Victor Y. Liu |
| collection | DOAJ |
| description | The management of cardiovascular disease in patients with active cancer presents a unique challenge in interventional cardiology. Cancer patients often suffer from significant comorbidities such as thrombocytopenia and coagulopathic and/or hypercoagulable states, which complicates invasive evaluation and can specifically be associated with an increased risk for vascular access complications. Furthermore, anticancer therapies cause injury to the vascular endothelium as well as the myocardium. Meanwhile, improvements in diagnosis and treatment of various cancers have contributed to an increase in overall survival rates in cancer patients. Proper management of this patient population is unclear, as cancer patients are largely excluded from randomized clinical trials on percutaneous coronary intervention (PCI) and national PCI registries. In this review, we will discuss the role of different safety measures that can be applied prior to and during these invasive cardiovascular procedures as well as the role of intravascular imaging techniques in managing these high risk patients. |
| first_indexed | 2024-12-11T03:37:38Z |
| format | Article |
| id | doaj.art-400cba4b5789471abebb079099a86348 |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-12-11T03:37:38Z |
| publishDate | 2018-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-400cba4b5789471abebb079099a863482022-12-22T01:22:12ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2018-05-01510.3389/fcvm.2018.00048317696Interventional Cardio-Oncology: Adding a New Dimension to the Cardio-Oncology FieldVictor Y. LiuAli M. AghaJuan Lopez-MatteiJuan Lopez-MatteiNicolas PalaskasPeter KimKara ThompsonElie MouhayarKonstantinos MarmagkiolisSaamir A. HassanKaveh KarimzadCezar A. IliescuThe management of cardiovascular disease in patients with active cancer presents a unique challenge in interventional cardiology. Cancer patients often suffer from significant comorbidities such as thrombocytopenia and coagulopathic and/or hypercoagulable states, which complicates invasive evaluation and can specifically be associated with an increased risk for vascular access complications. Furthermore, anticancer therapies cause injury to the vascular endothelium as well as the myocardium. Meanwhile, improvements in diagnosis and treatment of various cancers have contributed to an increase in overall survival rates in cancer patients. Proper management of this patient population is unclear, as cancer patients are largely excluded from randomized clinical trials on percutaneous coronary intervention (PCI) and national PCI registries. In this review, we will discuss the role of different safety measures that can be applied prior to and during these invasive cardiovascular procedures as well as the role of intravascular imaging techniques in managing these high risk patients.https://www.frontiersin.org/article/10.3389/fcvm.2018.00048/fullinterventional cardio-oncologyoptical coherence tomographyintravascular imagingthrombocytopeniafractional flow reserveinstantaneous free-wave ratio |
| spellingShingle | Victor Y. Liu Ali M. Agha Juan Lopez-Mattei Juan Lopez-Mattei Nicolas Palaskas Peter Kim Kara Thompson Elie Mouhayar Konstantinos Marmagkiolis Saamir A. Hassan Kaveh Karimzad Cezar A. Iliescu Interventional Cardio-Oncology: Adding a New Dimension to the Cardio-Oncology Field Frontiers in Cardiovascular Medicine interventional cardio-oncology optical coherence tomography intravascular imaging thrombocytopenia fractional flow reserve instantaneous free-wave ratio |
| title | Interventional Cardio-Oncology: Adding a New Dimension to the Cardio-Oncology Field |
| title_full | Interventional Cardio-Oncology: Adding a New Dimension to the Cardio-Oncology Field |
| title_fullStr | Interventional Cardio-Oncology: Adding a New Dimension to the Cardio-Oncology Field |
| title_full_unstemmed | Interventional Cardio-Oncology: Adding a New Dimension to the Cardio-Oncology Field |
| title_short | Interventional Cardio-Oncology: Adding a New Dimension to the Cardio-Oncology Field |
| title_sort | interventional cardio oncology adding a new dimension to the cardio oncology field |
| topic | interventional cardio-oncology optical coherence tomography intravascular imaging thrombocytopenia fractional flow reserve instantaneous free-wave ratio |
| url | https://www.frontiersin.org/article/10.3389/fcvm.2018.00048/full |
| work_keys_str_mv | AT victoryliu interventionalcardiooncologyaddinganewdimensiontothecardiooncologyfield AT alimagha interventionalcardiooncologyaddinganewdimensiontothecardiooncologyfield AT juanlopezmattei interventionalcardiooncologyaddinganewdimensiontothecardiooncologyfield AT juanlopezmattei interventionalcardiooncologyaddinganewdimensiontothecardiooncologyfield AT nicolaspalaskas interventionalcardiooncologyaddinganewdimensiontothecardiooncologyfield AT peterkim interventionalcardiooncologyaddinganewdimensiontothecardiooncologyfield AT karathompson interventionalcardiooncologyaddinganewdimensiontothecardiooncologyfield AT eliemouhayar interventionalcardiooncologyaddinganewdimensiontothecardiooncologyfield AT konstantinosmarmagkiolis interventionalcardiooncologyaddinganewdimensiontothecardiooncologyfield AT saamirahassan interventionalcardiooncologyaddinganewdimensiontothecardiooncologyfield AT kavehkarimzad interventionalcardiooncologyaddinganewdimensiontothecardiooncologyfield AT cezarailiescu interventionalcardiooncologyaddinganewdimensiontothecardiooncologyfield |